This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
Truncating mutations in <i>titin</i> (<i>TTN</i>) as a marker of dilated cardiomyopathy	Screening for truncating mutations in <i>TTN</i> could help diagnose dilated cardiomyopathy, a weakening of the cardiac muscle that can lead to congestive heart failure. Genome sequencing identified truncating mutations in <i>TTN</i> in 27% of dilated cardiomyopathy patients, 1% of hypertrophic cardiomyopathy patients and 3% of healthy controls. Next steps could include determining how truncations in <i>TTN</i> lead to disease. SciBX 5(13); doi:10.1038/scibx.2012.350 Published online March 29, 2012	Patent application filed; available for licensing	Herman, D.S. <i>et al.</i> <i>N. Engl. J. Med.</i> ; published online Feb. 16, 2012; doi:10.1056/NEJMoa1110186 Contact: Christine E. Seidman, Harvard Medical School, Boston, Mass. e-mail: cseidman@genetics.med.harvard.edu